DK0827509T3 - Modulering af cholesterylestertransferprotein-(CETP)-aktivitet - Google Patents

Modulering af cholesterylestertransferprotein-(CETP)-aktivitet

Info

Publication number
DK0827509T3
DK0827509T3 DK96913320T DK96913320T DK0827509T3 DK 0827509 T3 DK0827509 T3 DK 0827509T3 DK 96913320 T DK96913320 T DK 96913320T DK 96913320 T DK96913320 T DK 96913320T DK 0827509 T3 DK0827509 T3 DK 0827509T3
Authority
DK
Denmark
Prior art keywords
cetp
activity
transfer protein
cholesteryl ester
ester transfer
Prior art date
Application number
DK96913320T
Other languages
English (en)
Inventor
Lawrence J Thomas
Charles W Rittershaus
Original Assignee
Avant Immunotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avant Immunotherapeutics Inc filed Critical Avant Immunotherapeutics Inc
Application granted granted Critical
Publication of DK0827509T3 publication Critical patent/DK0827509T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0012—Lipids; Lipoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK96913320T 1995-05-01 1996-05-01 Modulering af cholesterylestertransferprotein-(CETP)-aktivitet DK0827509T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/432,483 US6410022B1 (en) 1995-05-01 1995-05-01 Modulation of cholesteryl ester transfer protein (CETP) activity

Publications (1)

Publication Number Publication Date
DK0827509T3 true DK0827509T3 (da) 2006-12-27

Family

ID=23716356

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96913320T DK0827509T3 (da) 1995-05-01 1996-05-01 Modulering af cholesterylestertransferprotein-(CETP)-aktivitet

Country Status (10)

Country Link
US (5) US6410022B1 (da)
EP (1) EP0827509B1 (da)
JP (1) JP3839483B2 (da)
AT (1) ATE336510T1 (da)
CA (1) CA2219795C (da)
DE (1) DE69636453T2 (da)
DK (1) DK0827509T3 (da)
ES (1) ES2271952T3 (da)
PT (1) PT827509E (da)
WO (1) WO1996034888A1 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410022B1 (en) * 1995-05-01 2002-06-25 Avant Immunotherapeutics, Inc. Modulation of cholesteryl ester transfer protein (CETP) activity
DE69626642T2 (de) 1995-06-06 2004-01-29 Avant Immunotherapeutics Inc Cetp zur erhöhung des hdl-cholesterol-gehalts
AU721729B2 (en) * 1996-05-01 2000-07-13 Avant Immunotherapeutics, Inc. Plasmid-based vaccine for treating atherosclerosis
US20030100520A1 (en) * 1997-01-21 2003-05-29 Philip Needleman Immunological process and constructs for increasing the hdl cholesterol concentration by dna vaccination
US20030026808A1 (en) * 1997-01-21 2003-02-06 Philip Needleman An IMMUNOLOGICAL PROCESS FOR INCREASING THE HDL CHOLESTROL CONCENTRATION
CA2302778A1 (en) * 1997-09-19 1999-04-01 Monsanto Company Dna vaccination against cholesterol ester transfer protein in the treatment of atherosclerosis
AU747709B2 (en) * 1997-10-20 2002-05-23 Avant Immunotherapeutics, Inc. Xenogeneic cholesteryl ester transfer protein (CETP) for modulation of CETP activity
EP1246597B1 (en) 1999-08-03 2015-01-14 The Ohio State University Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein
US6875904B2 (en) 2000-09-20 2005-04-05 The Ohio State University Research Foundation Animal model for identifying agents that inhibit or enhance CTLA4 signaling
DE10121982B4 (de) * 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
AU2002325827A1 (en) * 2001-06-07 2002-12-16 Genfit Compositions and methods for detecting or regulating cholesteryl ester transfer protein
WO2004000238A2 (en) * 2002-03-22 2003-12-31 Tittle Thomas V Utilization of mhc class ii binding motifs in immunization to produce immune serum, monoclonal antibodies and vaccines
ATE532793T1 (de) * 2003-07-03 2011-11-15 Avatar Biotechnologies Inc Verfahren zur herstellung von molekülen mit verminderter immunogenität
AT500835B1 (de) * 2004-09-13 2007-12-15 Affiris Forschungs & Entwicklungs Gmbh Cholinestertransport-protein-mimotop als atherosklerose-medikament
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US20060276400A1 (en) 2005-06-06 2006-12-07 Hedy Adari Modulation of cholesteryl ester transfer protein (CETP) activity
AU2006261342B2 (en) 2005-06-15 2012-02-02 The Ohio State University Research Foundation Her-2 peptides
US20090142362A1 (en) * 2006-11-06 2009-06-04 Avant Immunotherapeutics, Inc. Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP)
AT505574B1 (de) * 2007-08-10 2009-09-15 Affiris Forschungs & Entwicklungs Gmbh Mimotope zur behandlung von atherosklerose
EP2379547A1 (en) 2008-12-16 2011-10-26 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
US20100234283A1 (en) 2009-02-04 2010-09-16 The Ohio State University Research Foundation Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
CA2804604C (en) * 2010-07-08 2023-10-03 United Biomedical, Inc. Designer peptide-based pcv2 vaccine
EP2532359A1 (en) 2011-06-10 2012-12-12 Affiris AG CETP fragments
WO2013083254A1 (en) 2011-12-09 2013-06-13 Bavarian Nordic A/S Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c
MX347400B (es) 2012-06-29 2017-04-18 Univ Nac Autónoma De México Vacuna de aplicacion nasal contra el desarrollo de la enfermedad aterosclerotica y el higado graso.
SG11201507883SA (en) * 2013-03-29 2015-10-29 Sumitomo Dainippon Pharma Co Ltd Wt1-antigen peptide conjugate vaccine
WO2014157704A1 (ja) 2013-03-29 2014-10-02 大日本住友製薬株式会社 Ｅｒａｐ１によるトリミング機能をきっかけとしたコンジュゲートワクチン
TW201627318A (zh) * 2014-10-22 2016-08-01 臺北醫學大學 膽固醇酯轉運蛋白抗原肽及其融合蛋白以及其組合物及應用
US12383608B2 (en) 2016-11-30 2025-08-12 Sumitomo Pharma Co., Ltd. WT1 helper peptides and combinations of WT1 helper peptide and conjugate of cancer antigen peptides

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143305A (en) * 1973-05-07 2000-11-07 The Ohio State University Antigenically modified polypeptides composition
US5126399A (en) 1986-04-30 1992-06-30 Board Of Regents, The University Of Texas System Methods and compositions for the preparation and use of site-directed immunologic reagents
US5338829A (en) 1988-04-20 1994-08-16 Trustees Of The University Of Pennsylvania Peptides derived from human immunodeficiency virus-1 GP160
GB8812214D0 (en) 1988-05-24 1988-06-29 Hoffmann La Roche Use of peptide from circumsporozoite protein of p falciparum as universally recognized t-cell epitope
US5242687A (en) 1989-03-15 1993-09-07 Tkb Associates Limited Partnership Method of reducing cellular immune response involving T-cells using CD8-bearing antigen presenting cells
AU666473B2 (en) 1990-12-10 1996-02-15 Entremed, Inc A vaccine against cholesterol to prevent hypercholesterolemia and atherosclerosis
WO1993011782A1 (en) 1991-12-19 1993-06-24 Southwest Foundation For Biomedical Research Cetp inhibitor polypeptide, antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments
WO1993023076A1 (en) 1992-05-20 1993-11-25 The Johns-Hopkins University Alternative receptor therapy
US5662907A (en) * 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
US5618683A (en) 1993-04-13 1997-04-08 Brocia; Robert W. Diagnostic kit for cholesteryl ester transfer protein (CETP) activity measurement and a new synthetic particle used therein
US5759551A (en) * 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
WO1994025060A1 (en) 1993-04-27 1994-11-10 Ladd Anna E Immunogenic lhrh peptide constructs and synthetic universal immune stimulators for vaccines
DK96493D0 (da) 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
US5705388A (en) 1994-12-23 1998-01-06 Ribozyme Pharmaceuticals, Inc. CETP Ribozymes
US6410022B1 (en) * 1995-05-01 2002-06-25 Avant Immunotherapeutics, Inc. Modulation of cholesteryl ester transfer protein (CETP) activity
DE69626642T2 (de) 1995-06-06 2004-01-29 Avant Immunotherapeutics Inc Cetp zur erhöhung des hdl-cholesterol-gehalts
US5869057A (en) * 1995-06-07 1999-02-09 Rock; Edwin P. Recombinant vaccines to break self-tolerance
US5807552A (en) * 1995-08-04 1998-09-15 Board Of Regents, The University Of Texas System Compositions for conferring immunogenicity to a substance and uses thereof

Also Published As

Publication number Publication date
US20040087481A1 (en) 2004-05-06
ATE336510T1 (de) 2006-09-15
JP3839483B2 (ja) 2006-11-01
CA2219795A1 (en) 1996-11-07
AU5636096A (en) 1996-11-21
DE69636453T2 (de) 2007-03-29
US6410022B1 (en) 2002-06-25
AU707752B2 (en) 1999-07-22
US6555113B1 (en) 2003-04-29
US20030108559A1 (en) 2003-06-12
JPH11504635A (ja) 1999-04-27
DE69636453D1 (de) 2006-09-28
EP0827509A1 (en) 1998-03-11
WO1996034888A1 (en) 1996-11-07
US7078036B2 (en) 2006-07-18
PT827509E (pt) 2007-01-31
EP0827509B1 (en) 2006-08-16
ES2271952T3 (es) 2007-04-16
US20020042364A1 (en) 2002-04-11
CA2219795C (en) 2000-08-08

Similar Documents

Publication Publication Date Title
DK0827509T3 (da) Modulering af cholesterylestertransferprotein-(CETP)-aktivitet
DE69833886D1 (de) Inspections- und Bewertungssystem von Kondensatableiter
BR9605153B1 (pt) vacina de combinação, e, kit de vacinação.
DE3789724D1 (de) System zur Prüfung von interaktiver Software.
EE03424B1 (et) Allergiavastase valguhüdrolüsaadipreparaadi valmistamise meetod
TR199600357A2 (tr) Rekombinant simanlik (Ob) proteinleri.
DK0759944T3 (da) Forbedringer af og relateret til peptidfremføring
NO20001240D0 (no) Kay-A immunsystemprotein
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
DE3587549D1 (de) Ergänzungstestverfahren von proteine bindenden enzymen.
NO158164C (no) Fremgangsmaate for fremstilling av et enzymatisk hydrolysert proteinmateriale.
DE69834574D1 (de) Miscmicellen aus lipopeptiden für induzierung einer immunantwort
DE60039880D1 (en) Therapie mit lipoproteinlipase (lpl) variant
NO885013D0 (no) FremgangsmŸte for fremstilling av bionedbrytbare mikrokapsler av vannopplelige peptider og proteiner, samt mikroka psler oppnŸdd ved fremgangsmŸten.
DE69831500D1 (de) Humane checkpointkinase, hcds1, zusammensetzungen und verfahren
EP0218696A4 (en) Human anti-inflammatory phospholipase inhibitor protein.
WO1995015391A3 (en) Aspergillus expression system
DK0786004T3 (da) Kloning, ekspression og karakterisering af en hidtil ukendt form af phosphatidylinositol-3-kinase
ATE285474T1 (de) Haemophilus adhäsionsproteinen
ATE314474T1 (de) Klonering von dem gen für das t gondii protein gp 28.5 peptidfragmente aus diesem protein und ihre verwendungen.
NO972063L (no) Isolert BMP-reseptorkinaseprotein, DNA-sekvens, rekombinant ekspresjonsvektor samt vertscelle
WO1997008934A3 (en) Aryl acrylic acid derivatives useful as protein tyrosine phosphatase inhibitors
WO1996002572A3 (fr) Sequence polypeptidique antigenique du facteur viii, fragments et/ou epitopes de celle-ci
ES2308850T3 (es) Anticuerpos para antigenos de celulas de langerhans de mamiferos y sus usos.
DE68903930D1 (de) Lipidemulsion zur behandlung von aids.